JP2020531539A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531539A5 JP2020531539A5 JP2020511450A JP2020511450A JP2020531539A5 JP 2020531539 A5 JP2020531539 A5 JP 2020531539A5 JP 2020511450 A JP2020511450 A JP 2020511450A JP 2020511450 A JP2020511450 A JP 2020511450A JP 2020531539 A5 JP2020531539 A5 JP 2020531539A5
- Authority
- JP
- Japan
- Prior art keywords
- canakinumab
- patient
- use according
- recurrent
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229960001838 canakinumab Drugs 0.000 claims 31
- 230000002526 effect on cardiovascular system Effects 0.000 claims 18
- 208000010125 myocardial infarction Diseases 0.000 claims 16
- 108010074051 C-Reactive Protein Proteins 0.000 claims 11
- 230000000306 recurrent effect Effects 0.000 claims 9
- 102100032752 C-reactive protein Human genes 0.000 claims 3
- 206010002388 Angina unstable Diseases 0.000 claims 2
- 208000007814 Unstable Angina Diseases 0.000 claims 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 2
- 230000000250 revascularization Effects 0.000 claims 2
- 231100001160 nonlethal Toxicity 0.000 claims 1
- 238000011272 standard treatment Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549971P | 2017-08-25 | 2017-08-25 | |
| US62/549,971 | 2017-08-25 | ||
| US201762584380P | 2017-11-10 | 2017-11-10 | |
| US62/584,380 | 2017-11-10 | ||
| PCT/IB2018/056465 WO2019038737A1 (en) | 2017-08-25 | 2018-08-24 | USE OF CANAKINUMAB |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020531539A JP2020531539A (ja) | 2020-11-05 |
| JP2020531539A5 true JP2020531539A5 (https=) | 2021-09-30 |
Family
ID=63643018
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511441A Withdrawn JP2020531537A (ja) | 2017-08-25 | 2018-08-24 | カナキヌマブの使用 |
| JP2020511450A Withdrawn JP2020531539A (ja) | 2017-08-25 | 2018-08-24 | カナキヌマブの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511441A Withdrawn JP2020531537A (ja) | 2017-08-25 | 2018-08-24 | カナキヌマブの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20200199220A1 (https=) |
| EP (2) | EP3710475A1 (https=) |
| JP (2) | JP2020531537A (https=) |
| TW (2) | TW201919695A (https=) |
| WO (2) | WO2019038737A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021517141A (ja) * | 2018-03-09 | 2021-07-15 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 心血管疾患のための組み合わせ治療 |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
| CN113491820A (zh) * | 2021-07-30 | 2021-10-12 | 复旦大学附属中山医院 | 涂层Canakinumab的药物球囊的制备及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| BR112014007253A2 (pt) | 2011-09-30 | 2017-03-28 | Novartis Ag | uso de anticorpos que se ligam a il-1beta |
-
2018
- 2018-08-24 US US16/641,897 patent/US20200199220A1/en not_active Abandoned
- 2018-08-24 JP JP2020511441A patent/JP2020531537A/ja not_active Withdrawn
- 2018-08-24 US US16/641,889 patent/US20200239564A1/en not_active Abandoned
- 2018-08-24 EP EP18773257.3A patent/EP3710475A1/en not_active Withdrawn
- 2018-08-24 WO PCT/IB2018/056465 patent/WO2019038737A1/en not_active Ceased
- 2018-08-24 EP EP18773836.4A patent/EP3710476A1/en not_active Withdrawn
- 2018-08-24 TW TW107129672A patent/TW201919695A/zh unknown
- 2018-08-24 JP JP2020511450A patent/JP2020531539A/ja not_active Withdrawn
- 2018-08-24 WO PCT/IB2018/056468 patent/WO2019038740A1/en not_active Ceased
- 2018-08-27 TW TW107129849A patent/TW201919696A/zh unknown
-
2023
- 2023-03-21 US US18/187,242 patent/US20240043525A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aronow | Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure | |
| Tschoepe et al. | Heart failure with preserved ejection fraction: current management and future strategies: expert opinion on the behalf of the Nucleus of the “Heart Failure Working Group” of the German Society of Cardiology (DKG) | |
| Su et al. | Cardiovascular manifestation and treatment in COVID-19 | |
| JP2019514925A5 (https=) | ||
| JP2018193377A5 (https=) | ||
| HRP20221150T1 (hr) | Semaglutid u kardiovaskularnim stanjima | |
| JP2020531539A5 (https=) | ||
| JP2018111728A5 (https=) | ||
| Nativi-Nicolau et al. | Pharmacologic therapies for acute cardiogenic shock | |
| JP2019507797A5 (https=) | ||
| Iacoviello et al. | Recent advances in pharmacological treatment of heart failure | |
| JP2015522029A5 (https=) | ||
| JP2013505205A5 (https=) | ||
| Sardar et al. | Antiarrhythmic drug therapy for atrial fibrillation | |
| JP2015503593A5 (https=) | ||
| Siak et al. | The use of colchicine in cardiovascular diseases: a systematic review | |
| JP2019533715A5 (https=) | ||
| Soleimani et al. | The effect of intravenous N-acetylcysteine on prevention of atrial fibrillation after coronary artery bypass graft surgery: a double-blind, randomised, placebo-controlled trial | |
| MX380070B (es) | Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina. | |
| JP2020531537A5 (https=) | ||
| JP2017519762A5 (https=) | ||
| Chen et al. | Teaching an old dog new tricks: colchicine in cardiovascular medicine | |
| JP2016512247A5 (https=) | ||
| JP2021502379A5 (https=) | ||
| RU2018104691A (ru) | Композиции с модифицированным высвобождением ницерголина |